Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay

Molecular Diagnosis and Therapy

Volumn 19, Issue 3, 2015, Pages 159-167

  Song, Lele ^a,b   Yu, Haotian ^a   Li, Yuemin ^a  

^a 309TH HOSPITAL OF PLA   (China)

^b BioChain Beijing Science and Technology Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; SHOX2 PROTEIN; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; SHOX2 PROTEIN, HUMAN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; GENE FUNCTION; GENETIC PROCEDURES; HOMEOBOX; HUMAN; LUNG CANCER; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SHORT STATURE HOMEOBOX GENE; SHOX2 GENE METHYLATION ASSAY; SURVIVAL TIME; CLINICAL TRIAL (TOPIC); DNA METHYLATION; EARLY DIAGNOSIS; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EARLY DETECTION OF CANCER; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84931578102     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-015-0144-5     Document Type: Review

References (50)

1. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2013.
2. The 2014 annual cancer report of China, Beijing, China. The National Cancer Registry; 2014.
3. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2011. Bethesda: National Cancer Institute; 2014.
4. Lung cancer screening. Fort Washington: National Comprehensive Cancer Network; 2015.
5. Report on lung cancer screening. Chicago: American Lung Association; 2012.
6. Berg CD, Aberle DR, National Lung Screening Trial Executive Committee. CT screening for lung cancer. N Engl J Med. 2007;356:743–4 (author reply 746–747).
7. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
8. National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–91.
9. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013;369:920–31.
10. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793–802.
11. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest. 2003;123:115S–28S.
12. Roth K, Hardie JA, Andreassen AH, et al. Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulm Med. 2008;8:2.
13. Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer. 2010;10:600.
14. Dietrich D, Kneip C, Raji O, et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int J Oncol. 2012;40:825–32.
15. Ilse P, Biesterfeld S, Pomjanski N, et al. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. Cancer Genomics Proteomics. 2014;11:251–8.
16. Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011;6:1632–8.
17. Schneider KU, Dietrich D, Fleischhacker M, et al. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 2011;11:102.
18. Dietrich D, Hasinger O, Liebenberg V, et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21:93–104.
19. Darwiche K, Zarogoulidis P, Baehner K, et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol. 2013;24:2866–70.
20. Dietrich D, Jung M, Puetzer S, et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS One. 2013;8:e84225.
21. Ilse P, Biesterfeld S, Pomjanski N, et al. SHOX2 DNA methylation is a tumour marker in pleural effusions. Cancer Genomics Proteomics. 2013;10:217–23.
22. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16:54–63.
23. Ogata T. SHOX: pseudoautosomal homeobox containing gene for short stature and dyschondrosteosis. Growth Horm IGF Res. 1999;9(Suppl B):53–7 (discussion 57–58).
24. Blaschke RJ, Rappold GA. SHOX: growth, Léri-Weill and Turner syndromes. Trends Endocrinol Metab. 2000;11:227–30.
25. Rao E, Blaschke RJ, Marchini A, et al. The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator. Hum Mol Genet. 2001;10:3083–91.
26. Binder G. Short stature due to SHOX deficiency: genotype, phenotype, and therapy. Horm Res Paediatr. 2011;75:81–9.
27. Cobb J, Dierich A, Huss-Garcia Y, et al. A mouse model for human short-stature syndromes identifies Shox2 as an upstream regulator of Runx2 during long-bone development. Proc Natl Acad Sci. 2006;103:4511–5.
28. Yu L, Liu H, Yan M, et al. Shox2 is required for chondrocyte proliferation and maturation in proximal limb skeleton. Dev Biol. 2007;306:549–59.
29. Oliveira CS, Alves C. The role of the SHOX gene in the pathophysiology of Turner syndrome. Endocrinol Nutr. 2011;58:433–42.
30. Bobick BE, Cobb J. Shox2 regulates progression through chondrogenesis in the mouse proximal limb. J Cell Sci. 2012;125:6071–83.
31. Aza-Carmona M, Barca-Tierno V, Hisado-Oliva A, et al. NPPB and ACAN, two novel SHOX2 transcription targets implicated in skeletal development. PLoS One. 2014;9:e83104.
32. Espinoza-Lewis RA, Yu L, He F, et al. Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nk2–5. Dev Biol. 2009;327:376–85.
33. Liu H, Espinoza-Lewis RA, Chen C, et al. The role of Shox2 in SAN development and function. Pediatr Cardiol. 2012;33:882–9.
34. Sun C, Yu D, Ye W, et al. The short stature homeobox 2 (Shox2)-bone morphogenetic protein (BMP) pathway regulates dorsal mesenchymal protrusion development and its temporary function as a pacemaker during cardiogenesis. J Biol Chem. 2015;290:2007–23.
35. Yu L, Gu S, Alappat S, et al. Shox2-deficient mice exhibit a rare type of incomplete clefting of the secondary palate. Development. 2005;132:4397–406.
36. Scott A, Hasegawa H, Sakurai K, et al. Transcription factor short stature homeobox 2 is required for proper development of tropomyosin-related kinase B-expressing mechanosensory neurons. J Neurosci. 2011;31:6741–9.
37. Ellison JW, Wardak Z, Young MF, et al. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Hum Mol Genet. 1997;6:1341–7.
38. Belin V, Cusin V, Viot G, et al. SHOX mutations in dyschondrosteosis (Lòei-Weill syndrome). Nat Genet. 1998;19:67–9.
39. Shears DJ, Vassal HJ, Goodman FR, et al. Mutation and deletion of the pseudoautosomal gene SHOX cause Lòri-Weill dyschondrosteosis. Nat Genet. 1998;19:70–3.
40. De Baere E, Speleman F, Van Roy N, De Paepe A, Messiaen L. Assignment of SHOX2 (alias OG12X and SHOT) to human chromosome bands 3q25→q26.1 by in situ hybridization. Cytogenet Cell Genet. 1998;82:228–9.
41. Blaschke RJ, Monaghan AP, Schiller S, et al. SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development. Proc Natl Acad Sci. 1998;95:2406–11.
42. Semina EV, Reiter RS, Murray JC. A new human homeobox gene OGI2X is a member of the most conserved homeobox gene family and is expressed during heart development in mouse. Hum Mol Genet. 1998;7:415–22.
43. Clement-Jones M, Schiller S, Rao E, et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9:695–702.
44. Blaschke RJ, Hahurij ND, Kuijper S, et al. Targeted mutation reveals essential functions of the homeodomain transcription factor Shox2 in sinoatrial and pacemaking development. Circulation. 2007;115:1830–8.
45. Ehrlich M, Gama Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucleic Acids Res. 1982;10:2709–21.
46. Tucker KL. Methylated cytosine and the brain: a new base for neuroscience. Neuron. 2001;30:649–52.
47. Craig JM, Wong NC, editors. Epigenetics: a reference manual. Caister Academic Press; 2011, ISBN 978-1-904455-88-2.
48. Daura-Oller E, Cabre M, Montero MA, et al. Specific gene hypomethylation and cancer: new insights into coding region feature trends. Bioinformation. 2009;3:340–3.
49. Newnham GM, Conron M, McLachlan S, et al. Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer. 2011;11:93.
50. Schmidt B, Beyer J, Dietrich D, et al. Quantification of cell-free mSHOX2 plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS One. 2015;10:e0118195.